Anika Therapeutics, Inc. Announces Executive Changes, Effective August 10, 2020
August 06, 2020 at 01:39 am IST
Share
Anika Therapeutics, Inc. announced the appointment of Michael Levitz as Executive Vice President and Treasurer, starting August 10, 2020. He succeeds Sylvia Cheung, who will continue with the Company in an advisory capacity for a period following the succession effective date to assist with a smooth transition. Prior to joining Anika, Mr. Levitz served as Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global innovative medical device and drug delivery company. Prior to Insulet, from 2009 to 2015 he was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz served in various capacities including Vice President and Corporate Controller. Mr. Levitz began his career in the high technology audit practice at Arthur Andersen.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.